Display options
Cite
Pollera CF, Marolla P, Nardi M, et al. Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects. Cancer Chemother Pharmacol. 1988;21(1):61-4doi: 10.1007/BF00262741.
Pollera, C. F., Marolla, P., Nardi, M., Ameglio, F., Cozzo, L., & Bevere, F. (1988). Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects. Cancer chemotherapy and pharmacology, 21(1), 61-4. https://doi.org/10.1007/BF00262741
Pollera, C F, et al. "Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects." Cancer chemotherapy and pharmacology vol. 21,1 (1988): 61-4. doi: https://doi.org/10.1007/BF00262741
Pollera CF, Marolla P, Nardi M, Ameglio F, Cozzo L, Bevere F. Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects. Cancer Chemother Pharmacol. 1988;21(1):61-4. doi: 10.1007/BF00262741. PMID: 3342465.
Copy Download .nbib Format: NLM
Share it on

Cancer Chemother Pharmacol. 1988;21(1):61-4. doi: 10.1007/BF00262741.

Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects.

Cancer chemotherapy and pharmacology

C F Pollera, P Marolla, M Nardi, F Ameglio, L Cozzo, F Bevere

Affiliations

  1. Regina Elena Institute for Cancer Research, Rome, Italy.

PMID: 3342465 DOI: 10.1007/BF00262741

Abstract

Acute and subacute audiometric hearing changes were evaluated in 12 patients receiving 35 courses of very high-dose (vhd) cisplatin (200 mg/m2 per course) in hypertonic saline at 4 or 8-week intervals. Audiogical evaluations were performed both before and immediately after each course of chemotherapy, and again after the discontinuation of treatment. A significant drop of the mean hearing threshold (P less than 0.01) at high frequencies was observed even within 48 h from the end of the first course of therapy, with 50% of the patients presenting a hearing loss of more than 15 dB. At the same total dose (200 mg/m2), one course of this regimen provided an incidence of hearing loss of more than 15 dB, which was four times greater than that reported with two courses of standard-dose regimens. The incidence and severity of the hearing impairment progressed further with subsequent courses of chemotherapy. Compared with baseline levels, most patients (75%) receiving at least two courses had a moderate to severe hearing loss, especially involving 4 and 8 kHz. At the end of treatment, 33% of the patients complained of a nondisabling functional hearing impairment. No recovery occurred after chemotherapy had been discontinued for 9-28 weeks. At this dose level cisplatin is markedly ototoxic. The use of hypertonic saline and vigorous hydration are effective means of minimizing the risk of nephrotoxicity, but seem to have no effect on cisplatin-related ototoxicity.

References

  1. Cancer. 1974 Oct;34(4):1005-10 - PubMed
  2. J Clin Oncol. 1985 Dec;3(12):1683-9 - PubMed
  3. Cancer Chemother Pharmacol. 1985;14(1):38-41 - PubMed
  4. Cancer. 1983 Feb 15;51(4):610-3 - PubMed
  5. Cancer. 1977 Apr;39(4):1372-81 - PubMed
  6. J Clin Oncol. 1985 Sep;3(9):1246-50 - PubMed
  7. Am J Obstet Gynecol. 1981 Oct 1;141(3):309-12 - PubMed
  8. Cancer Chemother Rep. 1974 Nov-Dec;58(6):871-5 - PubMed
  9. Laryngoscope. 1982 Dec;92(12):1408-13 - PubMed
  10. Toxicol Appl Pharmacol. 1981 Oct;61(1):99-108 - PubMed
  11. Ann Intern Med. 1985 May;102(5):719 - PubMed
  12. Cancer Res. 1983 Mar;43(3):1187-94 - PubMed
  13. J Surg Oncol. 1981;16(2):111-23 - PubMed
  14. Laryngoscope. 1983 Dec;93(12):1554-9 - PubMed
  15. Clin Toxicol. 1978;13(4):469-78 - PubMed
  16. Ann Intern Med. 1984 Jan;100(1):19-24 - PubMed
  17. Eur J Cancer Clin Oncol. 1983 Jan;19(1):53-8 - PubMed
  18. J Clin Oncol. 1987 Feb;5(2):318-9 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources